Bristol Myers Squibb vs Zeffy

Side-by-side comparison of AI visibility scores, market position, and capabilities

Bristol Myers Squibb leads in AI visibility (75 vs 26)

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
B75
Category Rank
#112 of 290
AI Consensus
59%
Trend
stable
Per Platform
ChatGPT
67
Perplexity
77
Gemini
84

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

Zeffy

EmergingNonprofit Tech

Zero-Fee Fundraising

Montreal zero-fee nonprofit fundraising platform with $1B+ processed; 100% donation pass-through via optional donor tips competing with Donorbox and Classy for nonprofit fundraising technology adoption.

AI VisibilityBeta
Overall Score
D26
Category Rank
#1 of 1
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
19
Perplexity
26
Gemini
17

About

Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs rather than deducting fees from each donation, ensuring 100% of every donated dollar reaches the nonprofit cause. Founded in 2019 by Thibaut Davoult and Nicolas Lafleur, Zeffy has processed $1+ billion in nonprofit donations and provides a comprehensive suite including online donation forms, event ticketing, peer-to-peer fundraising campaigns, recurring donation management, and membership management — giving nonprofits a full fundraising platform at genuinely zero cost.

Full profile

AI Visibility Head-to-Head

75
Overall Score
26
#112
Category Rank
#1
59
AI Consensus
68
stable
Trend
stable
67
ChatGPT
19
77
Perplexity
26
84
Gemini
17
81
Claude
29
72
Grok
18

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.